SINTX Technologies (SINT) Announces $5M Private Placement at $3.45/sh

SINTX Technologies, Inc., (Nasdaq: SINT), a leader in advanced ceramics for medical applications, today announced that it has, pursuant to a securities purchase agreement with institutional and accredited investors dated February 20, 2025, issued and sold 1,449,287 shares of common stock (or pre-funded warrants in lieu therof) at a purchase price of $3.45 per share (or pre-funded warrant in lieu thereof) in a private placement priced at-the-market under Nasdaq rules. In addition, the Company issued to the investors in the offering unregistered warrants (the “warrants”) to purchase up to an aggregate of 1,449,287 shares of common stock. The warrants are exercisable immediately at an exercise price of $3.32 per share and will expire five and one-half years from the date of issuance. The offering closed on February 25, 2025.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The aggregate gross proceeds to the Company from the private placement were approximately $5 million before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital purposes.

The shares of common stock, pre-funded warrants and warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”) and Regulation D promulgated thereunder and, along with the shares of common stock underlying the pre-funded warrants and warrants, have not been registered under the Act or applicable state securities laws. Accordingly, the shares of common stock, the pre-funded warrants, the warrants and the shares of common stock underlying the pre-funded warrants and warrants may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. Pursuant to a registration rights agreement, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock and the shares issuable upon exercise of the pre-funded warrants and warrants.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• enVVeno Medical (NVNO) files $100M mixed shelf
• Aveanna Healthcare prices secondary offering at $11.75 per share
• Singularity Future Technology closes $5M registered direct offering